The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in
asymptomatic heart failure subjects will improve their heart structure and thus prevent the
progression to symptomatic disease.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Birmingham, Alabama, United States
Mobile, Alabama, United States
Little Rock, Arkansas, United States
Riverside, California, United States
Redondo Beach, California, United States
Los Angeles, California, United States
Northridge, California, United States
Research Site, Farmington, Connecticut, United States
Vero Beach, Florida, United States
Melbourne, Florida, United States
Clearwater, Florida, United States
Augusta, Georgia, United States
Jeffersonville, Indiana, United States
Indianapolis, Indiana, United States
Edgewood, Kentucky, United States
Shreveport, Louisiana, United States
New Orleans, Louisiana, United States
Auburn, Maine, United States
Baltimore, Maryland, United States
Salisbury, Maryland, United States
Boston, Massachusetts, United States
St. Charles, Missouri, United States
St. Louis, Missouri, United States
Omaha, Nebraska, United States
Albuquerque, New Mexico, United States
Bronx, New York, United States
Williamsville, New York, United States
New York, New York, United States
Rochester, New York, United States
E. Syracuse, New York, United States
Buffalo, New York, United States
Burlington, North Carolina, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Flourtown, Pennsylvania, United States
Lincoln, Rhode Island, United States
Wakefield, Rhode Island, United States
Tyler, Texas, United States
Salt Lake City, Utah, United States
Roanoke, Virginia, United States
Chesapeake, Virginia, United States
Green Bay, Wisconsin, United States